Healthcare Resource Optimization of Different Formulations: Daratumumab SC Compared To Daratumumab IV for Treating Multiple Myeloma
Author(s)
Xuan Mo, MSc, Hongyu Wang, MSc, Han Yang, MSc, Jun Liu, PhD, Jian Ming, PhD.
IQVIA, Shanghai, China.
IQVIA, Shanghai, China.
Presentation Documents
OBJECTIVES: This study aims to explore healthcare resource optimization of two different formulations in an example of Daratumumab subcutaneous (SC) compared to Daratumumab intravenous (IV) in Chinese healthcare context.
METHODS: A two-phase survey, consisting of four in-depth interviews and seventy online questionnaires with hematologists, was conducted to collect the information upon physicians’ clinical experience. Information and suggestions from in-depth interviews were used to design the online questionnaire. Descriptive statistics were conducted to summarize results.
RESULTS: The hematologists investigated in this survey were all experienced in multiple myeloma (MM) from twenty-nine tier-3 hospitals. The analyzed results showed Daratumumab SC was estimated to save an average of 26 CNY on managing infusion-related reactions (IRR) and 956 CNY per person per year on corticosteroid administration compared to Daratumumab IV. As Daratumumab SC reduced substantial duration of drug delivery and was associated with fewer IRRs, it resulted in a reduction in hospitalization rates for administration compared to Daratumumab IV (26% and 29% for initial and subsequent treatment, respectively) and increased rates in outpatient or day ward settings, saving 1,762 CNY per person per year. With a shorter administration time, Daratumumab SC could save 929 CNY, 2,975 CNY and 1,227 CNY per person per year in contrast to IV formulation for electrocardiogram monitoring, catheterization and catheterization-related adverse events, respectively. For MM patients with heart/kidney dysfunction, hypercalcemia, anemia, or obesity, Daratumumab SC was estimated to reduce additional medical interventions, saving 2,565 CNY versus Daratumumab IV per person per year. Overall, MM patients receiving Daratumumab SC could save an average of 10,439 CNY per person per year on healthcare resources compared to Daratumumab IV.
CONCLUSIONS: These results suggest that Daratumumab SC is expected to result in reduced patient treatment burden and increase healthcare resource utilization compared to IV infusion.
METHODS: A two-phase survey, consisting of four in-depth interviews and seventy online questionnaires with hematologists, was conducted to collect the information upon physicians’ clinical experience. Information and suggestions from in-depth interviews were used to design the online questionnaire. Descriptive statistics were conducted to summarize results.
RESULTS: The hematologists investigated in this survey were all experienced in multiple myeloma (MM) from twenty-nine tier-3 hospitals. The analyzed results showed Daratumumab SC was estimated to save an average of 26 CNY on managing infusion-related reactions (IRR) and 956 CNY per person per year on corticosteroid administration compared to Daratumumab IV. As Daratumumab SC reduced substantial duration of drug delivery and was associated with fewer IRRs, it resulted in a reduction in hospitalization rates for administration compared to Daratumumab IV (26% and 29% for initial and subsequent treatment, respectively) and increased rates in outpatient or day ward settings, saving 1,762 CNY per person per year. With a shorter administration time, Daratumumab SC could save 929 CNY, 2,975 CNY and 1,227 CNY per person per year in contrast to IV formulation for electrocardiogram monitoring, catheterization and catheterization-related adverse events, respectively. For MM patients with heart/kidney dysfunction, hypercalcemia, anemia, or obesity, Daratumumab SC was estimated to reduce additional medical interventions, saving 2,565 CNY versus Daratumumab IV per person per year. Overall, MM patients receiving Daratumumab SC could save an average of 10,439 CNY per person per year on healthcare resources compared to Daratumumab IV.
CONCLUSIONS: These results suggest that Daratumumab SC is expected to result in reduced patient treatment burden and increase healthcare resource utilization compared to IV infusion.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE151
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology, STA: Biologics & Biosimilars